C1INH administered subcutaneously was licensed for LTP in HAE, as were the kallikrein inhibitor lanadelumab and the first oral treatment option berotralstat (also an inhibitor of plasma kallikrein). The gene discussed is SERPING1; the disease is hereditary angioedema.